WuXi Biologics is trading HK$43.14 (+4.25%) as stronger biotech-sector sentiment follows Argenx’s tender offer for Forte Biosciences.
- The XBI ETF is up 2.09%, supporting the broader sector move.
- No fresh company-specific announcement directly explaining the August 7 move was identified; the latest company-related item was an August 25 board meeting to review interim results.
- The move therefore appears sector-driven, though confidence is limited by the absence of multiple direct reports.